PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

被引：0
|
作者：
Paz-Ares, L. [1 ]
Goldman, J. W. [2 ]
Garassino, M. C. [3 ]
Dvorkin, M. [4 ]
Trukhin, D. [5 ]
Statsenko, G. [6 ]
Hotta, K. [7 ]
Ji, J. H. [8 ]
Hochmair, M. J. [9 ]
Voitko, O. [10 ]
Havel, L. [11 ]
Poltoratskiy, A. [12 ]
Losonczy, G. [13 ]
Reinmuth, N. [14 ]
Shrestha, Y. [15 ]
Patel, N. [16 ]
Mann, H. [17 ]
Jiang, H. [18 ]
Ozguroglu, M. [19 ]
Chen, Y. [20 ]
机构：
[1] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Med, Los Angeles, CA 90095 USA
[3] Ist Nazl Tumori, Fdn IRCCS, Thorac Unit, Milan, Italy
[4] BHI Omsk Reg Clin Oncol Dispensary, Dept Oncol, Omsk, Russia
[5] Natl Med Univ, Oncol Dept, Odessa, Ukraine
[6] Omsk Reg Canc Ctr, Dept Med Oncol, Omsk, Russia
[7] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan
[8] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Internal Med, Chang Won, South Korea
[9] Krankenhaus Nord, Dept Resp & Crit Care Med, Karl Landsteiner Inst Lung Res & Pulm Oncol, Krankenhaus Nord, Vienna, Austria
[10] Kyiv City Clin Oncol Ctr, Dept Chemotherapy, Kiev, Ukraine
[11] Charles Univ Prague, Thomayer Hosp, Fac Med 1, Prague, Czech Republic
[12] Petrov Res Inst Oncol, Dept Preclin & Clin Trials, St Petersburg, Russia
[13] Semmelweis Univ, Fac Med, Budapest, Hungary
[14] Asklepios Lung Clin, Thorac Oncol, Munich, Germany
[15] AstraZeneca, Translat Med, Gaithersburg, MD USA
[16] AstraZeneca, Patient Reported Outcomes, Gaithersburg, MD USA
[17] AstraZeneca, Res & Dev, Cambridge, MD USA
[18] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[19] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Dept Internal Med, Istanbul, Turkey
[20] Canc & Hematol Ctr Western Michigan, Med Oncol, Grand Rapids, MI USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA89
引用
收藏
页码：928 / +
页数：2
相关论文
共 50 条
  • [41] Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
    Cho, B. C.
    Rodriguez-Abreu, D.
    Hussein, M.
    Cobo, M.
    Patel, A.
    Secen, N.
    Gerstner, G.
    Kim, D-W.
    Lee, Y-G.
    Su, W-C.
    Huang, E.
    Patil, N.
    Huang, M.
    Zhang, Z.
    Wen, X.
    Mendus, D.
    Hoang, T.
    Meng, R.
    Johnson, M. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1428 - S1428
  • [42] Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial
    Makharadze, T.
    Quek, R. G.
    Melkadze, T.
    Gogishvili, M.
    Ivanescu, C.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Moreno-Jaime, B.
    Passalacqua, R.
    Konidaris, G.
    Rietschel, P.
    Gullo, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1414 - S1414
  • [43] Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.
    Gumus, Mahmut
    Chen, Chieh-I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation
    Baramidze, A.
    Gessner, C.
    Gogishvili, M.
    Sezer, A.
    Makharadze, T.
    Kilickap, S.
    Gumus, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S70 - S71
  • [45] Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
    Zandberg, Dan P.
    Algazi, Alain P.
    Jimeno, Antonio
    Good, James S.
    Fayette, Jerome
    Bouganim, Nathaniel
    Ready, Neal E.
    Clement, Paul M.
    Even, Caroline
    Jang, Raymond W.
    Wong, Stuart
    Keilholz, Ulrich
    Gilbert, Jill
    Fenton, Moon
    Brana, Irene
    Henry, Stephanie
    Remenar, Eva
    Papai, Zsuzsanna
    Siu, Lillian L.
    Jarkowski, Anthony
    Armstrong, Jon M.
    Asubonteng, Kobby
    Fan, Jean
    Melillo, Giovanni
    Mesia, Ricard
    EUROPEAN JOURNAL OF CANCER, 2019, 107 : 142 - 152
  • [46] Nivolumab (Nivo) plus Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
    Reck, Martin
    Hellmann, Matthew David
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Brahmer, Julie R.
    O'Byrne, Kenneth John
    Bhagavatheeswaran, Prabhu
    Nathan, Faith Ellen
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)
    Agarwal, Neeraj
    Azad, Arun
    Matsubara, Nobuaki
    Saad, Fred
    De Giorgi, Ugo
    Joung, Jae Young
    Fong, Peter C. C.
    Jones, Robert J.
    Zschaebitz, Stefanie
    Oldenburg, Jan
    Shore, Neal D.
    Dunshee, Curtis
    Carles, Joan
    Fay, Andre P.
    Cislo, Paul
    Chang, Jane
    Healy, Cynthia G.
    Niyazov, Alexander
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Impact of tislelizumab plus chemotherapy versus placebo plus chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial.
    Yoon, Harry H.
    Xu, Jianming
    Kato, Ken
    Pan, Yueyin
    Park, Sook Ryun
    Shen, Lin
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Barnes, Frederick
    Sun, Tianmo
    Barnes, Gisoo
    Victor, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 366 - 366
  • [49] EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)
    Soo, R.
    Mok, T. S. K.
    Shi, Y-K.
    Zhang, L.
    Lu, S.
    Yang, J. C-H.
    Nakagawa, K.
    Yamamoto, N.
    Nokihara, H.
    Sugawara, S.
    Nishio, M.
    Takahashi, T.
    Goto, K.
    Chang, J.
    Maemondo, M.
    Ichinose, Y.
    Cheng, Y.
    Lim, W.
    Morita, S.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Nivolumab (Nivo) plus platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.
    Borghaei, Hossein
    Hellmann, Matthew David
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Reck, Martin
    O'Byrne, Kenneth John
    Bhagavatheeswaran, Prabhu
    Nathan, Faith Ellen
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345